Navigation Links
Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
Date:6/10/2008

PITTSBURGH, June 10 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it has signed a license and supply agreement with NATCO Pharma Ltd. (NATCO) for NATCO's glatiramer acetate pre-filled syringes, a generic version of Teva's Copaxone(R), which is used to treat multiple sclerosis. The agreement grants Mylan exclusive distribution rights in the United States and all major markets in Europe, Australia, New Zealand, Japan and Canada and includes an option to expand into additional territories.

NATCO has commercialized successfully its glatiramer acetate product in India and the Ukraine. Teva has reported that worldwide sales of Copaxone were more than $1.7 billion in 2007.

"We are extremely pleased to be collaborating with NATCO to market and distribute this critically important product virtually worldwide," said Robert J. Coury, Mylan vice chairman and CEO. "We've worked closely with NATCO over the past several months, and we're excited to have completed this agreement. During that time, we have been impressed with the company's long-term vision and outstanding technical capabilities, which are clearly reflected in NATCO's ability to develop a complex product such as generic Copaxone. We plan to work closely with all relevant regulatory agencies in the United States and internationally -- and leverage Mylan's considerable global expertise in regulatory applications -- to bring the therapeutic and economic benefits of this product to the widest possible patient-base."

"We had spoken with several potential partners since we launched glatiramer as a generic in India last year," said NATCO Chairman and Managing Director Chowadary V. Nannapaneni. "After an extensive review, we believe that no company is better positioned than Mylan to help us unlock the extraordinary value of this product in the United States and around the world. We are truly excited about our collaboration."

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies

NATCO Pharma Limited, based in Hyderabad, India, is ranked among the fastest growing pharmaceutical companies in the country. It manufactures branded and generic dosage forms, bulk actives and intermediates for Indian and international markets. During its 24-year history, NATCO has gained a reputation for innovative product development, high-quality manufacturing capabilities and strong financial growth.

Copaxone(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Announces Final FDA Approval for Zaleplon Capsules
2. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
3. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
4. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
5. Mylan Declares Quarterly Preferred Stock Dividend
6. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
7. Mylan Announces Final FDA Approval for Trandolapril Tablets
8. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
9. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
10. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
11. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... The Wickman Agency in Garland, TX has ... community. Pledging to select a new beneficiary every 60 days, the agency will ... is to bring community awareness to important local causes by forming campaigns which ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... Boston, MA (PRWEB) , ... February 10, 2016 , ... ... light switch, and brings pain that is often severe, with intense swelling and redness. ... more than eight million people, but older adults are the most susceptible, according to ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... measure change in their patients. Research shows that the Goal Attainment Scale (GAS) ... therapists overcome this challenge and learn more about the Goal Attainment Scale, Education ...
(Date:2/10/2016)... MD (PRWEB) , ... February 10, 2016 , ... ... to make Everseat digital self-scheduling readily available to physicians. The integration ... patients can find and select appointments via Everseat’s free mobile app. , The ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... February 10, 2016 --> ... research report "Pharmaceutical Packaging Equipment Market by Package Type ... Serialization), by Product Type (Tablet, Powder, Cream, Syrup, Aseptic ... MarketsandMarkets, studies the global market during the forecast period of ... at a CAGR of 6.9% during the forecast period ...
(Date:2/10/2016)... 2016 On Tuesday, February 9th, the ... with its Arthritis Advisory Committee to discuss ... & Johnson,s Remicade and most likely the ... U.S. The Biologics Prescribers Collaborative (BPC) along ... for Patient Access, American Association of Clinical ...
(Date:2/10/2016)... 10, 2016 --> ... Therapeutics and Companion Diagnostic Market to 2019 - ... Environment" research report indicates that the core personalized ... by 2020 growing at a CAGR of 8.74%. ... and targeted therapeutics and is dominated by oncology, ...
Breaking Medicine Technology: